This site is intended for UK healthcare professionals only



Keep up to date with the latest news on bladder health, management and treatment.

Have you got a story to share? Email the team today.

5 April 2023
Urinary Incontinence
Luja™ shows significant improvement in bladder emptying

Study results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow* in 90% of catheterisations.

Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male catheter, designed to reduce the risk of urinary tract infections by minimising residual urine and reducing bladder microtrauma1.

The study’s primary endpoints were urinary flow-stop episodes and residual volume at first flow-stop. A flow-stop occurs when bladder mucosa is sucked into the catheter eyelets, thereby blocking the urine flow. A blockage requires repositioning of the catheter in order to resume the urine flow to empty the bladder2. Additionally, hematuria was assessed by dipstick, and post-catheterisation volume of residual urine was measured with an ultrasound bladder scanner.

Statistically significant results
A selection of the data from the study, which showed statistically significant results, was presented at the United Kingdom Continence Society (UKCS) Annual Scientific Meeting in Sheffield, UK, on 30 March3

  • Catheterisation with Luja resulted in close to zero flow-stops compared to one flow-stop on average with VaPro*.
  • Luja achieved complete bladder emptying* in 90% of catheterisations, while VaPro achieved this in 52% of catheterisations.
  • Catheterisation with Luja resulted in a 74% less likelihood of hematuria post-catheterisation, compared to VaPro.

“I am very pleased with the results of the Luja CP353 study. All primary and secondary endpoints have been successfully met, and the study clearly demonstrates that Luja significantly improves bladder emptying. I am excited by what Luja can do for people who use intermittent catheters to empty their bladder, and I look forward to following the launch in the coming months,” says Nicolai Buhl, Executive Vice President of Innovation at Coloplast.

The CP353 study
Urinary tract infections represent a significant challenge for people who use intermittent catheters to empty their bladder, and on average users experience 2-3 urinary tract infections per year1,4. Almost half of intermittent catheter users are unsure whether their bladder has been fully emptied after catheterisation4.

When emptying the bladder with conventional eyelet catheters, the flow of urine can be interrupted because the bladder mucosa surrounding the eyelets is sucked into the catheter**. These flow-stops can give users the false impression that their bladder is empty3, potentially leading to premature removal of the catheter and residual urine left behind in the bladder. To release the mucosa from the eyelets, and resume flow, users are required to reposition the catheter which can result in microtrauma**. Residual urine and microtrauma are both important risk factors for urinary tract infections1,,5-6. Consequently, users of conventional eyelet catheters are exposed to both these risk factors1 when they perform their catheterisation.

The CP353 study investigated the performance of Coloplast’s new intermittent male catheter, Luja, with 80+ micro-holes designed to reduce urinary flow-stops and minimise residual urine. The investigation was a single-centre, crossover, randomized and controlled study, which consisted of one inclusion visit and two single test visits. A total of 42 subjects enrolled were catheterized by a healthcare professional with a Luja catheter and a VaPro catheter 3.

Read more news from The Bladder Interest Group now.

  1. Kennelly M, et al. Adult Neurogenic Lower Urinary Tract Dysfunction and Intermittent Catheterisation in a Community Setting: Risk Factors Model for Urinary Tract Infections. Advances in urology. 2019:2757862
  2. Vahr et al. Catheterisation Urethral Intermittent in Adults. Arnhem, Netherlands: European Association of Urology Nurses (EAUN); 2013.
  3. M.H. Landauro, et al. Micro-hole zone technology shows superior ability to empty the bladder: a crossover randomised controlled trial in users of intermittent catheters. UKCS Annual Scientific Meeting; Sheffield, United Kingdom 2023.
  4. Islamoska et al. Nov 2022. Patient-reported risk factors for urinary tract infections are associated with lower quality of life among users of clean intermittent catheterisation. Poster at BAUN (Coloplast user survey 2022 (n=3464)
  5. Grabe et al. Guidelines on urological infections. EAU Guidelines presented at the 26th EAU Annual Congress, Vienna. 2013:78-93.
  6. Vasudeva and Madersbacher. Factors implicated in pathogenesis of urinary tract infections in neurogenic bladders: some revered, few forgotten, other ignored. Neurourol Urodyn. 2014;33(1):95-100.

View clinical trial

Latest News

Artificial Intelligence used in bladder cancer treatment assessment

A computerised artificial intelligence (AI)-based decision support system (CDSS-T) enhanced the performance of clinicians when assessing patients’ response to chemotherapy prior to radical cystectomy, according to results from a small multi-institutional observer...

New treatment for urothelial cancer approved by NICE

Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment for urothelial cancer – avelumab – following its recommendation for routine NHS funding in final draft guidance published NICE. The recommendation for this...